On Friday, May 23, 2025, Indoco Remedies share price surged as much as 6.38%, hitting an intraday high of ₹258.20. Around 12:10 PM, the stock was up 1.77%, trading at ₹247, while the BSE Sensex was up 0.90% at 81,678.93.
The stock rose after Indoco Remedies received final approval from the USFDA (United States Food and Drug Administration) to market Allopurinol Tablets USP, 200 mg, in the US. This approval was granted through the company's Abbreviated New Drug Application (ANDA).
The approved drug is a generic version of Zyloprim 200 mg, a medicine by Casper Pharma LLC. Allopurinol is commonly used to reduce high uric acid levels, particularly in patients with gout, cancer treatments, or kidney stones.
Indoco expressed its excitement about the approval, stating it reflects their ability to produce high-quality medicines and marks an important step in their growth journey in the US market.
Managing Director Aditi Panandikar commented:
“This development showcases Indoco's commitment to quality and gives a strong push to our growth in a key market like the US.”
The Allopurinol tablets will be manufactured at Indoco's facility in Verna, Goa.
Also Read: GMR Airports To Acquire Stake in BD General Aviation Services!
Indoco Remedies Ltd is a fully integrated pharmaceutical company with a strong focus on research and innovation. It has:
The share price jump was driven by a major USFDA approval that strengthens Indoco’s presence in the US, highlighting its strong R&D capabilities and commitment to growth.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 23, 2025, 2:07 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
